Akineton

Country: Аустралија

Језик: Енглески

Извор: Department of Health (Therapeutic Goods Administration)

Купи Сада

Активни састојак:

Biperiden hydrochloride

Информативни летак

                                AKINETON
biperiden hydrochloride 2 mg tablet
CONSUMER MEDICINE INFORMATION
_Date of Dispensing_
_Consumer Name_
_Pharmacist Name_
_Consumer Address_
_Pharmacist Address_
WHAT IS IN THIS LEAFLET
This leaflet answers some common 
questions about AKINETON.
It does not contain all the available 
information.
It does not take the place of talking to 
your doctor or pharmacist.
All medicines have risks and 
benefits
.
Your doctor has weighed 
the risks of you taking AKINETON 
against the benefits they expect it will 
have for you.
IF YOU HAVE ANY CONCERNS ABOUT 
TAKING THIS MEDICINE, ASK YOUR 
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT AKINETON IS USED 
FOR
AKINETON is used to treat 
symptoms of parkinsonism.
The symptoms of parkinsonism 
include slow and unsteady 
movement, muscle stiffness and 
shaking (tremors).  If untreated 
parkinsonism can cause difficulty in 
performing normal daily activities.
Symptoms of parkinsonism can be 
caused by certain diseases of the 
brain affecting movement, such as 
Parkinson’s disease.  They can also 
be caused by some medicines that 
are used to treat certain mental 
conditions.
It is believed the symptoms of 
parkinsonism are caused by a lack of 
dopamine, a naturally occurring 
chemical produced by certain brain 
cells.  When not enough dopamine is 
present, acetylcholine which is 
another naturally occurring chemical 
produced by brain cells, can interfere 
with the regions of the brain that 
control muscle movement.
AKINETON blocks the effects of 
acetylcholine.  In many patients, this 
reduces the symptoms of shaking 
and muscle stiffness.  
AKINETON is also used to treat 
cramps that occur during the night.
AKINETON belongs to a group of 
medicines called anticholinergics.  It 
is available as tablets.
Your doctor may have prescribed 
AKINETON for another reason.  Ask 
your doctor if you have any questions 
about why AKINETON has been 
prescrib
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                PRODUCT INFORMATION
AKINETON (biperiden hydrochloride 2 mg tablet
)
NAME OF THE MEDICINE
Biperiden hydrochloride. 
The structural formula for biperiden is shown below: 
CAS Number: 514-65-8
DESCRIPTION
Biperiden  is  a  white,  crystalline,  odourless  powder,  slightly  soluble  in  water  and 
alcohol. It is stable in air at normal temperatures. Biperiden is α-5-norbornen-2-yl-α-
phenyl-1-piperidine propanol. Its molecular weight is 311.5. The molecular weight of 
the hydrochloride salt is 347.9.
Biperiden  hydrochloride  tablet  2mg  is  equivalent  to  1.8mg  biperiden.  Biperiden 
tablets  contain  the  following inactive  ingredients: starch  – maize,  calcium  hydrogen 
phosphate, cellulose – microcrystalline, povidone, lactose, talc – purified, magnesium 
stearate, water – purified and starch – pregelatinised potato.
INDICATIONS
Akineton is indicated for the treatment of parkinsonism, drug-induced extrapyramidal 
symptoms,  pyramidal  spasticity,  closed  crani-ocerebral  trauma  and  post-concussion 
symptoms, trigeminal neuralgia and nocturnal cramps.
CONTRAINDICATIONS
Known hypersensitivity to biperiden hydrochloride
or to any of the components in the 
medication, narrow angle glaucoma, mechanical stenoses of the gastrointestinal tract, 
in megacolon and in ileus.
PRECAUTIONS
Akineton should be administered with caution to patients with prostatic hypertrophy 
with accumulation of residual urine.
In  a  few  cases,  especially  in  patients  with  prostatic  adenoma,  Akineton  may  cause 
disturbances of micturition calling for a reduction of the dose, rarely anuria (antidote: 
carbachol).
Akineton should be administered with caution in conditions which may be associated 
with  significant  tachycardia  or  in  patients  who  show  an  increased  tendency  to 
convu
                                
                                Прочитајте комплетан документ
                                
                            

Обавештења о претрази у вези са овим производом

Погледајте историју докумената